. 2010 Dec 29;6(6):919–925. doi: 10.5114/aoms.2010.19302

Table I.

Comparative data of FEV %, PEFR%, serum nitric oxide (NO) and Eosin% at baseline and 8 weeks after treatment

	Group 1 (n = 11) (Montelukast)		Group 2 (n = 11) Fluticasone)		Group 3 (n = 10) (SR-Theophylline)		Group 4 (n = 7) (No medication)
	Baseline	Day 56	Baseline	Day 56	Baseline	Day 56	Baseline	Day 56
	$\bar{X}$ ± SD	$\bar{X}$ ± SD	$\bar{X}$ ± SD	$\bar{X}$ ± SD	$\bar{X}$ ± SD	$\bar{X}$ ± SD	$\bar{X}$ ± SD	$\bar{X}$ ± SD
Age	10.0 ±1.95		9.7 ±2.01		9.6 ±0.97		9.9 ±2.91
FEV₁%	68 ±10^*	78 ±13^*	72 ±15	81 ±11	76 ±9^*	86 ±11^*	75 ±14	73 ±21
PEFR%	63 ±17^*	76 ±11^*	59 ±15^*	75 ±15^*	65 ±18	73 ±11	67 ±19	62 ±17
NO [μmol/l]	4.9 ±3.9^*	2.2 ±2.1^*	3.2 ±2.5^*	1.4 ±1.7^*	3.7 ±2.4	2.3 ±2.7	2.4 ±3.6	4.5 ±5.2
Eosin%	6.0 ±2.0^*	3.0 ±1.0^*	9.0 ±4.0^*	4.0 ±3.0^*	5.0 ±3.0^*	2.0 ±2.0^*	3.0 ±2.0	2.0 ±1.0

* p = significant (p < 0.05) improvement in parameter after 8 weeks of treatment; for FEV % p = 0.007 and 0.012 (in groups 1 and 3 respectively for PEFR% p = 0.028 and 0.003 (in groups 1 and 2 respectively); for NO p = 0.041 and 0.026 (in groups 1 and 2 respectively); and for Eosin% p = 0.001, 0.000 and 0.002 (in groups 1, 2 and 3 respectively)

FEV₁%–forced expiratory flow rate at first second as percentage of that predicted, PEFR%–peak expiratory flow rate as percentage of tha predicted, Eosin%–eosinophil count as percentage of eosinophils